Brief

AMR Policy Dialogue: Driving Innovative Solutions for Antimicrobial Discovery

Published on 1 June 2022

Antimicrobial resistance (AMR) is a global strategic priority and sits within the UK Government’s National Risk Register. By 2050, AMR is predicted to cause 10 million deaths, more than cancer. In 2019 alone, there were an estimated 4.95 million deaths associated with bacterial AMR.

Although global pharmaceutical research and development (R&D) spend continues to increase year on year, research into antimicrobial drug discovery is not currently an attractive commercial investment. This has had two major consequences: an ongoing decline of human capital for R&D in this field, and a decline over the longer term in availability of therapeutically effective antibiotics and other antimicrobial agents.

Concerted and coordinated efforts are needed to translate high-level policy commitments into strategic actions for long-term funding and support for the R&D of new antimicrobials.

Cite this publication

Ghionis, A.; Barker, T. and Dowson, C. (2022) AMR Policy Dialogue: Driving Innovative Solutions for Antimicrobial Discovery

Authors

Tom Barker

Senior Health & Nutrition Convenor

Alexander Ghionis

Christopher Dowson

Publication details

published by
University of Warwick
language
English

Share

About this publication

Related content

Brief

Key considerations: Introducing experimental vaccines during health emergencies

SSHAP Briefing

28 May 2025

Brief

Supporting the mpox response for people with diverse sexual orientation, gender identity and/or gender expression in contexts where their rights are restricted

SSHAP Briefing

21 May 2025

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.